Jan Leendert B.
- Country
- The Netherlands
- Department
- Program Management
Research Overview
- Phase 1 Study on Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Chronic Heart Failure Patients
- Phase I Evaluation of [68Ga]Ga-DWJ155 in Patients with Advanced Breast Cancer and Non-Small Cell Lung Cancer (NSCLC)
- Evaluation of the Safety and Tolerability of AC01 in Patients with Heart Failure
Data & Insights
Has run more than one trial at 1 of 13 partner sites.
Specializations
Cardiovascular Medicine
A clinical investigator specializing in heart failure management and cardiovascular therapeutics. Their research activities center on evaluating novel therapeutic approaches for patients with cardiac conditions.
- Heart Failure Treatment
- Cardiovascular Therapeutics
- Cardiac Patient Care
The investigator focuses on understanding treatment tolerability and safety profiles in cardiovascular medicine.
Clinical Safety Assessment
Dedicated to investigating the safety and tolerability profiles of emerging therapeutic agents. Their work emphasizes comprehensive evaluation of treatment responses in cardiac patients.
- Drug Safety Evaluation
- Patient Monitoring
- Treatment Response Assessment
Their research expertise includes systematic assessment of therapeutic interventions in cardiovascular conditions.
Therapeutic Development
Involved in advancing therapeutic innovations for cardiovascular care, with particular attention to novel treatment approaches for heart failure patients.
- Innovative Therapies
- Treatment Development
- Clinical Applications
The investigator contributes to the evaluation of new therapeutic options in cardiovascular medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.